Lublin

• A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Parsacl … Recruiting
  2022-501687-18-00 4 2020-10-28 Advanced malignancies and IAI diseases
• Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by … Recruiting
  2024-516739-29-00 4 2019-01-23 Relapsing-remitting multiple sclerosis
• EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting
  2025-523975-48-00 5 2026-05-08 Obesity
• A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D … Recruiting
  2025-523123-22-00 5 2026-05-07 Chronic Kidney Disease
• COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME Recruiting
  2025-523937-25-00 5 2026-05-06 Diabetic Macular Edema (DME)
• Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Recruiting
  2025-523974-18-00 5 2026-04-30 Obesity
• A Phase 3 Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less … Recruiting
  2025-522567-15-00 5 2026-04-28 Plaque Psoriasis
• A research study comparing how well different doses of the medicine NNC0662-0419 lower blood sugar in people with type 2 diabetes Recruiting
  2025-523260-20-00 4 2026-04-28 type 2 diabetes
• HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting
  2025-523717-29-00 5 2026-04-28 HFpEF or HFmrEF and obesity
• A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa Recruiting
  2025-522440-41-00 4 2026-04-27 Hidradenitis Suppurativa
• A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi … Recruiting
  2025-521546-23-00 5 2026-04-21 Secondary progressive multiple sclerosis
• A clinical study to investigate the efficacy and safety of an investigational combination therapy with BNT324 and BNT327 in patients with ad … Recruiting
  2024-520238-31-01 9 2026-04-20 Advanced Lung Cancer
• A Phase 2 Study of Lesigercept (YH35324) in Adult Patients with Chronic Spontaneous Urticaria (CLEAR) Recruiting
  2025-524006-14-00 4 2026-04-20 Chronic Spontaneous Urticaria
• An investigational trial to evaluate the effects of the drug XC001 delivered via a catheter in subjects with chronic angina caused by corona … Recruiting
  2024-514874-36-01 4 2026-04-17 Refractory angina due to obstructive coronary artery disease
• Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting
  2025-521456-35-00 4 2026-04-13 Mild to moderate asthma
• Phase 3 Study of Barzolvolimab in Participants with Cold Induced Urticaria and Symptomatic Dermographism Recruiting
  2025-522583-32-00 5 2026-04-13 Cold-Induced Urticaria and Symptomatic Dermographism
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes ( ENLIGHTEN-1). Recruiting
  2025-523657-34-00 5 2026-04-13 Obesity
• Phase 3 Efficacy and Safety of Lebrikizumab in Adults With Nummular Eczema (LUMINE) Recruiting
  2025-522403-17-00 5 2026-04-10 Nummular Dermatitis
• A Study of Eloralintide (LY3841136) in Participants with Obesity or Overweight, and Type 2 Diabetes (ENLIGHTEN-2) Recruiting
  2025-523658-15-00 5 2026-04-10 Obesity
• A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination with Atezolizumab … Recruiting
  2024-517490-24-00 4 2026-03-31 Small Cell Lung Cancer
• A study to learn if galvokimig is safe and works in adults with moderate to severe atopic dermatitis Recruiting
  2025-522578-35-00 4 2026-03-30 Atopic Dermatitis
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting
  2025-521036-11-00 5 2026-03-23 Immune system disseases
• A study to learn about the effectiveness and safety of different doses of JNJ-88545223 in people with active psoriatic arthritis Recruiting
  2025-523141-10-00 4 2026-03-20 Active Psoriatic Arthritis
• Phase III Study of Rilvegostomig in Combination withBevacizumab with or without Tremelimumab as First-lineTreatment of Hepatocellular Carcin … Recruiting
  2024-518210-81-00 5 2026-03-18 Advanced Hepatocellular Carcinoma

Showing 145–168 of 786 trials